-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
Lino Pharmaceuticals
Shandong Linyi Pharmaceutical Co., Ltd., established in 2002, is a wholly-owned subsidiary of Shandong Keyuan Pharmaceutical Co., Ltd. (stock code: 301281.SZ), a leading domestic enterprise in the chemical raw material medicine segment. It focuses on the R&D, production, and sales of chemical pharmaceutical preparations, having established a comprehensive product line in chronic disease areas such as hypoglycemic agents, cardiovascular drugs, and central nervous system drugs, accumulating strong R&D capabilities. In recent years, the company has adopted a development strategy of "one body, two wings, and three pillars," focusing on technological R&D, implementing digital manufacturing, and promoting cultural marketing. It has built a complete industrial system that integrates raw materials and preparations and connects the entire upstream and downstream chain, gradually expanding its market competitive advantage.
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline